Medtronic Q1 Revenue Beats, Raises FY27 Outlook on 13.7% Organic Growth
MDT sits 30% above its 52-week low of $73.31.
Summary
Medtronic delivered a strong fiscal Q1 with revenue of $9.76B, beating the $9.54B consensus, and raised full-year guidance. Organic revenue growth hit 13.7%, led by an 18.9% surge in Cardiovascular, and adjusted EPS rose 15.1%. The company now expects FY27 organic revenue growth of 7.25%-7.75% and non-GAAP EPS of $5.94-$6.00, up from prior guidance. An extra fiscal week added about $570M to the quarter, but the beat and guidance raise still reflect broad-based momentum. This follows the 8-K filed this morning and comes after a $700M investment in Cornerstone Robotics announced earlier today, underscoring an active growth agenda. The stock trades at 15x forward earnings versus 12x three months ago, reflecting improved sentiment.
At the time of this announcement, MDT was trading at $94.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $116B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.